Sernova Corp. (TSE:SVA) Forecasted to Earn FY2025 Earnings of ($0.10) Per Share

Sernova Corp. (TSE:SVA) – Equities researchers at Ventum Cap Mkts issued their FY2025 earnings per share (EPS) estimates for shares of Sernova in a report issued on Tuesday, September 17th. Ventum Cap Mkts analyst S. Quenneville expects that the company will earn ($0.10) per share for the year. Ventum Cap Mkts currently has a “Strong-Buy” rating on the stock. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share.

Sernova (TSE:SVA) last announced its earnings results on Monday, September 16th. The company reported C($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.03) by C$0.01.

A number of other equities research analysts also recently weighed in on the company. Ventum Financial lowered their price target on Sernova from C$3.00 to C$2.50 and set a “buy” rating for the company in a report on Friday, September 13th. Leede Financial lowered their price target on Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating for the company in a report on Friday, September 13th.

Sernova Price Performance

Shares of TSE SVA opened at C$0.25 on Thursday. Sernova has a twelve month low of C$0.20 and a twelve month high of C$0.83. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The company has a market capitalization of C$79.48 million, a price-to-earnings ratio of -1.88 and a beta of 1.38. The business has a 50 day simple moving average of C$0.26 and a 200-day simple moving average of C$0.36.

Insider Buying and Selling

In related news, Director Steven Sangha sold 930,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total transaction of C$223,200.00. Insiders purchased a total of 379,600 shares of company stock worth $97,671 in the last three months. 12.98% of the stock is owned by insiders.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.